Recent achievements and perspectives of topotecan in the treatment of lung cancer;Topotecan, recenti acquisizioni e prospettive nel trattamento dei tumori del polmone

Tumori

Volumn 85, Issue 6 SUPPL. 1, 1999, Pages

  Gridelli, Cesare ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

NSCLC; SCLC; Topotecan

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN; VINCRISTINE;

BRAIN METASTASIS; CANCER RADIOTHERAPY; CONFERENCE PAPER; DRUG EFFECT; DRUG FORMULATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS INHIBITION; RADIOSENSITIZATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CEREBELLAR NEOPLASMS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TOPOTECAN;

EID: 0033374812     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Ardizzoni A., Hansen H., Dombernowsky P., Ganucci T., Kaplan S., Postmus P., Giaccone G., Schaefer B., Wander S., Verweij J.: Topotecan, a new active drug in the second-line treatment of small cell lung cancer: a phase I study in patients with refractory and sensitive disease. J. Clin. Oncol., 15: 2090-2096, 1997.
2. Cole J.L., Rinaldi D.A., Lormand N.A., Brierre J.E., Barnes B., Fontenot M.F., Buller E.J., Rainey J.: A phase I-II trial of topotecan (TOP) and gemcitabine (GEM) for patients with previously treated advanced non small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 18: 499a, 1999.
3. Dabrow M.B., Gilman P.B., Meyer T.J.: Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 18: 500a, 1999.
4. Depierre A., von Pawel J., Hans K., Mono D., Clark J., Gatzemeir V., Paillot N., Scheithauer W., Carmichael J., Santoro A., Ross G., Marangolo M.: Evualuation of topotecan (Hycamtin) in relapsed small cell lung cancer (SCLC). A multicenter phase II study. Lung Cancer; 18 (suppl 1): 13, 1997.
5. Eckardt J., Depierre A., Ardizzoni A., von Pawel J., Fields J.: Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol., 16: 452a, 1997.
6. Eckardt J., Gralla R., Palmer M.C., Gandara D., Laplante J., Sandler A., Fields S.Z., Fitts D., Broom C.: Topotecan (T) as second-line therapy in patients (pts) with small cell lung cancer (SCLC): a phase II study. Ann. Oncol., 7 (suppl 5): 107, 1996.
7. Eckardt J., Palmer M.C., Fanucchi M., Martins H., Gralla R., Poulin R., Fields S.Z.: Oral topotecan (T) as single agent first line treatment for patients (pts) with extensive disease (ED) small cell lung cancer (SCLC) inelegible for standard IV therapy: a phase II study. Proc. Am. Soc. Clin. Oncol., 18: 501a, 1999.
8. Frasci G., Panza N., Comella P., Cartenì G., Guida T., Nicolella G.P., Natale M., Lombardi R., Apicella A., Pacilio C., Gravina A., Lapenta L., Comella G.: Cisplatin, topotecan, paclitaxel weekly administration with G-CSF support for ovarian and small cell lung cancer patients: a dose-finding study. Ann. Oncol., 10: 355-358, 1999.
9. Jacobs S.A., Jett J.R., Belani C.P., Long G.S., Day R.D., Kim H.D., Levitt M.L., Wooley P.V.: Topotecan and paclitaxel, an active couplet, in untreated extensive disease small cell lung cancer. Lung Cancer; 18 (suppl 1): 13, 1997.
10. Jett J.R., Day R., Levitt M., Wooley G., Jacobs S.: Topotecan and paclitaxel, in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy. Proc. Am. Soc. Clin. Oncol., 18: 470a, 1999.
11. Kindler H.L., Kris M.G., Smith I.E., Miller V.A., Grant S.L., Krebs J.B., Ross G.A., Slevin M.L.: Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non small cell lung cancer. Am. J. Clin. Oncol., 21: 438-441, 1998.
12. Korfel A., von Pawel J., Dehm E., Keppler U., Deppermann M., Guttler I., Thiel E.: Response of symptomatic brain metastases of small cell lung cancer (SCLC) to topotecan also after preceeding whole-brain irradiation (WBI). Eur. J. Cancer, 35 (suppl 4): S251, 1999.
13. Lynch T.J., Herndon J., Lilenbaum R.C., Lyss A., Miller A.A., Green M.R.: Toxicity of paclitaxel (P) and topotecan (T) in patients with previuosly untreated extensive small cell lung cancer (E-SCLC). Proc. Am. Soc. Clin. Oncol., 18: 515a, 1999.
14. Lynch Jr T.J., Kalish L., Strauss G., Elias A., Skarin A., Shulman L.N., Posner M., Frei III E.: Phase II study of topotecan in metastatic non small cell lung cancer. J. Clin. Oncol., 12: 347-352, 1994.
15. Mainwaring P.N., Nicolson M.C., Hickish T., Penson R., Joel S., Slevin M., Smith I.E.: Continuous infusional topotecan in advanced breast and non small cell lung cancer: no evidence of increased efficacy. Br. J. Cancer; 76: 1636-1639, 1997.
16. Manegold C., von Pawel J., Scheithauer W., Lan J., Schaefer B., Pastovic R., Staab H.J.: Response of SCLC brain metastases on topotecan (SKF 104864) therapy. Ann. Oncol., 7 (suppl 5): 106, 1996.
17. Murren J., Kraut E., Balcerzak S., Gams R., Galloway S., Schultz M., Masters G., Chang A.: Phase II trial of topotecan and cyclophopshamide (Cy) with G-CSF in high-risk small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol., 17: 495a, 1998.
18. Panza N., Frasci G., Comella P., Nicolella G., Natale M., Muci D., Palmieri S., Ruffolo P., Gravina A., Comella G.: Cisplatin, paclitaxel, topotecan (CPT) weekly administration in chemo-naive or pretreated extensive disease small cell lung cancer (EL-SCLC). A SICOG phase II study. Eur. J. Cancer; 35 (suppl 4): S252, 1999.
19. Perez-Soler R., Fossella F.V., Glisson B.S., Lee J.S., Murphy W.K., Shin D.M., Kemp B.L., Lee J.J., Kane J., Robinson R.A., Lippman S.M., Kurie J.M., Huber M.H., Raber M.N., Hong W.K.: Phase II study of topotecan in patients with advanced non small cell lung cancer previously untreated with chemotherapy. J. Clin. Oncol., 14: 503-513, 1996.
20. Perez-Soler R., Glisson B.S., Lee J.S., Fossella F.V., Murphy W.K., Skin D.M., Hong W.K.: Treatment of refractory patients with non small cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J. Clin. Oncol., 14: 2785-2790, 1996.
21. Raefsky E.L., Hainsworth J.D., Burris H.A., Hopkins L.G., Greco F.A.: Phase I trial of topotecan, paclitaxel and carboplatin in patients with advanced refractory malignancies, Proc. Am. Soc. Clin. Oncol., 17: 498a, 1998.
22. Raymond E., Burris H.A., Rowinsky E.K., Eckardt J.R., Rodriguez G., Smith L., Welss G., von Hoff D.D.: Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non small cell lung cancer. Ann. Oncol., 8: 1003-1008, 1997.
23. Schiller J.H., Kim K., Hutson P., Devore R., Glick J., Stewart J., Johnson D.: Phase II study of topotecan in patients with extensive stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol., 14: 2345-2352, 1996.
24. Smith M.J., Spencer S.A., Zhang R., Robert F.: Phase I/IIa study of sequential ifosfamide (I) and topotecan (T) in patients with small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 17: 500a, 1998.
25. Sorensen M., Sensen P.B., Sehested M., Hirsch F.R., Hansen H.H.: Phase I/II study of topotecan and cisplatin alternating with carboplatin, cisplatin, teniposide and vincristine in previously untreated patients with small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 17: 501a, 1998.
26. Tweedy C.R., Andrews D.F., Ball T.: Topotecan and paclitaxel in extensive stage small cell lung cancer as initial therapy. Proc. Am. Soc. Clin. Oncol., 18: 525a, 1999.
27. von Pawel J., Depierre A., Hans K.: Topotecan (Hycamtin) in small cell lung cancer (SCLC) after failure of first line therapy: multicenter phase II study. The European Cancer Conference, Poster 1038, September, 1997.
28. von Pawel J., Gatzmeier V., Harstrick A., Ronson M., Richardson G., Steppert K., Comlett I., Lane S., Ross G.: A multicenter randomised phase II study of oral topotecan versus IV topotecan for second line therapy in sensitive patients with small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 18: 471a, 1999.
29. von Pawel J., Schriller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., Stewart D.J., Clark P.I., Palmer M.C., Depierre A., Carmichael J., Krebs J.B., Ross G., Lane S.R., Gralla R.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small cell lung cancer. J. Clin. Oncol., 17: 658-667, 1999.
30. Wiesenfeld M., Marks R., Grill J., Sloan J., Tazeelar H., Carrol T., Kugler J., Krook J.: A randomized phase II study of topotecan (TOP) and cisplatin (CDDP) with filgrastim (G-CSF) versus topotecan and paclitaxel (taxol) with filgrastim in patients with advanced non small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 18: 527a, 1999.
31. White S.C., Cheeseman S., Anderson H., Thatcher N., Hearn S., Ross G., Ranson M.: A phase II study of oral topotecan in advanced non small cell lung cancer: useful symptom palliation and 10 months median survival. Proc. Am. Soc. Clin. Oncol., 16:488a, 1997.